A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD.
COG # AAML1031
This study is for newly diagnosed patients with Acute Myeloid Leukemia (AML). AML is a cancer of the bone marrow, the spongy tissue inside the bones of the body where blood cells are made.
- Patients must be less than 30 years of age at the time of study enrollment.
- Be newly diagnosed with AML
- Agree to have bone marrow specimens sent to special COG labs prior to the start of treatment and at various times during treatment.
- Patients with Down's syndrome are not eligible
Mandy Atkinson, M.D.
Wendy McCarty, Clinical Research Coordinator